Regeneron (REGN) | Stock Overview & Key Data
Regeneron Performance Comparison
Stock Range
Today's Range
Low: $558.06
High: $567.69
on August 8, 2025
52 Week Range
Low: $476.49
High: $1,211.20
on June 5, 2025
on August 27, 2024
All-Time High: $1,211.20 on August 26, 2024
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$60.4B
EPS
39.66
P/E Ratio (TTM)
14.37
Forward P/E
12.57
P/B Ratio
1.98
PEG Ratio
12.57
Div. Yield
0.46%
ROE
15.34%
Beta
0.327
Debt to Equity
9.04
Financial Highlights
Profitability
Gross Margin
85.58%
Operating Margin
29.64%
Profit Margin
31.37%
Returns and Earnings
Return on Assets (TTM)
6.66%
Return on Equity (TTM)
15.34%
EBITDA
$5.1B
Net Income (TTM)
$4.5B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$129.67
Quarterly Revenue Growth (YoY)
3.60%
Quarterly Earnings Growth (YoY)
-2.80%
Dividend Information
Last 12-Month Dividend
$2.64
Current Dividend Yield
0.46%
3-Year Average Dividend Yield
0.14%
3-Year Average Annual Dividend
$0.88
3-Year Total Dividends
$2.64
Ex-Dividend Date
August 18, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Regeneron REGN | 60.39B Large-cap | 2.63% | 4.03% | -0.20% | -21.15% | -21.73% | -50.93% | -11.70% | -9.38% |
| Vertex VRTX | 121.28B Large-cap | -17.78% | -18.24% | -13.61% | -19.96% | -7.43% | -17.68% | 30.94% | 44.28% |
| Alnylam ALNY | 56.22B Large-cap | 10.93% | 34.24% | 57.33% | 57.54% | 86.24% | 61.48% | 86.11% | 219.69% |
| Royalty Pharma plc RPRX | 21.19B Large-cap | 0.57% | 3.99% | 13.01% | 16.64% | 43.51% | 41.36% | -16.02% | -18.26% |
| Insmed INSM | 21.13B Large-cap | 1.88% | 12.74% | 60.08% | 36.71% | 56.25% | 50.39% | 308.14% | 317.96% |
| Incyte INCY | 15.24B Large-cap | 4.42% | 16.25% | 31.32% | 5.49% | 12.47% | 27.13% | 4.95% | -18.15% |
Ownership & Short Interest
Insider Ownership
1.94%
Institutional Ownership
93.68%
Shares Short
2M
Short Ratio
2.06
Short % of Shares Outstanding
2.06%
Average 10-Day Volume
918K
Average 90-Day Volume
932K
Regeneron Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Regeneron would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is REGN's 52-week high and low?
- In the last 52 weeks, Regeneron reached a high of $1,211.20 (on August 27, 2024) and a low of $476.49 (on June 5, 2025).
- What is the market cap and P/E ratio for REGN?
- Curious about Regeneron's size and valuation? Its market capitalization stands at 60.39B. When it comes to valuation, the P/E ratio (trailing twelve months) is 14.37, and the forward P/E (looking ahead) is 12.57.
- Does REGN pay dividends? If so, what's the yield?
- Yes, Regeneron is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.46%, and the company has paid an average of $0.88 per share annually over the past 3 years.
- Who are Regeneron's main competitors or similar companies to consider before investing?
When looking at Regeneron, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX121.28B Healthcare Biotechnology -17.68% 30.94% Alnylam
ALNY56.22B Healthcare Biotechnology 61.48% 86.11% Royalty Pharma plc
RPRX21.19B Healthcare Biotechnology 41.36% -16.02% Insmed
INSM21.13B Healthcare Biotechnology 50.39% 308.14% Incyte
INCY15.24B Healthcare Biotechnology 27.13% 4.95% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Regeneron Pharmaceuticals, Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Regeneron's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 15.34%, the Debt to Equity ratio from the most recent quarter is 9.04, and its Gross Profit Margin stands at 85.58%.
- What is the recent revenue and earnings growth for REGN?
- Looking at Regeneron's growth, its revenue over the trailing twelve months (TTM) was $14B. Compared to the same quarter last year (YoY), quarterly revenue grew by 3.60%, and quarterly earnings saw a YoY growth of -2.80%.
- How much of REGN stock is held by insiders and institutions?
- Wondering who owns Regeneron stock? Company insiders (like executives and directors) hold about 1.94% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 93.68%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.